diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5792diaendo-5792Research ArticleСтатьиArticlesСистема остеопротегерин (OPG) -лиганд рецептора-активатора ядерного фактора каппа-В (RANKL) при диабетической нейроостеоартропатии и облитерирующем атеросклерозе артерий нижних конечностейSistema osteoprotegerin (OPG) -ligand retseptora-aktivatora yadernogo faktora kappa-V (RANKL) pri diabeticheskoy neyroosteoartropatii i obliteriruyushchem ateroskleroze arteriy nizhnikh konechnosteyЯрославцеваMarianna ВикторовнаYaroslavtsevaМарианна Viktorovna-УльяноваИрина НиколаевнаUl'yanovaIrina Nikolaevna-ГалстянГагик РадиковичGalstyanGagik Radikovich-ФГУ Эндокринологический научный центр Росмедтехнологий, МоскваEndocrinology Research Centre, Moscow200715062007102№2 (2007)2427Copyright © Ярославцева M.В., Ульянова И.Н., Галстян Г.Р., 20072007Ярославцева M.В., Ульянова И.Н., Галстян Г.Р.Yaroslavtseva М.V., Ul'yanova I.N., Galstyan G.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5792

Экспериментальные и клинические исследования свидетельствуют о том, что система OPG/RANKL не только регулирует ремоделирование костной ткани, но и принимает участие в развитии патологии сосудов. В связи с этим приобретает актуальность разработка терапевтических исходов, направленных на увеличение концентрации OPG в костной ткани и сосудистой стенке.

остеопротегеринРАНКЛдиабетическая нейроостеоартропатияоблитерирующий атеросклерозReferencesДедов И.И., Шестакова М.В. (2003) Сахарный диабет. Руководство для врачей. М.: Универсум Паблишинг - с.263Дедов И.И., Шестакова М.В. (2003) Сахарный диабет. Руководство для врачей. М.: Универсум Паблишинг - с.263Дедов И.И., Чазова Т.Е., Сунцов Ю.И. (2003) Эпидемиология сахарного диабета. Пособие для врачей. М. - с.56Дедов И.И., Чазова Т.Е., Сунцов Ю.И. (2003) Эпидемиология сахарного диабета. Пособие для врачей. М. - с.56Jeffcoate W. (2004) Vascular calcification and osteolysis in diabetic neuropathy - is RANK-L the missing link? Diabetologia . 47:1488-1492Jeffcoate W. (2004) Vascular calcification and osteolysis in diabetic neuropathy - is RANK-L the missing link? Diabetologia . 47:1488-1492Miazgovski T., Andrysiak-Mamos E., Pynka S., Gulinska M., Czekalski S. (1997) The evaluation of bone mineral density and selected markers of bone turnover in patients with insulin-dependent diabetes mellitus. Przegl Lek; 54 (7-8): 533-539.Miazgovski T., Andrysiak-Mamos E., Pynka S., Gulinska M., Czekalski S. (1997) The evaluation of bone mineral density and selected markers of bone turnover in patients with insulin-dependent diabetes mellitus. Przegl Lek; 54 (7-8): 533-539.Miazgovski T., Czekalski S. (1998) A 2-year follow-up study on bone mineral density and markers of bone turnover in patients with long-standing insulin-dependent diabetes mellitus. Osteoporos Int. ; 8 (5):399-403.Miazgovski T., Czekalski S. (1998) A 2-year follow-up study on bone mineral density and markers of bone turnover in patients with long-standing insulin-dependent diabetes mellitus. Osteoporos Int. ; 8 (5):399-403.Selby P.L., Jude E.B., et al. (2000) Bone turnover markers in acute Charcot neuroarthropathy. Diabetologia. Sept; 44: A 275Selby P.L., Jude E.B., et al. (2000) Bone turnover markers in acute Charcot neuroarthropathy. Diabetologia. Sept; 44: A 275Gough A., Abraha H., Li F., Purewall T.S., Foster A.V., Watkins P.J., Moniz C., Edmonds M.E. (1997) Measurement of markers of osteoclast and osteoblast activity in Patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet.Med. July; 14(7):527-531.Gough A., Abraha H., Li F., Purewall T.S., Foster A.V., Watkins P.J., Moniz C., Edmonds M.E. (1997) Measurement of markers of osteoclast and osteoblast activity in Patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet.Med. July; 14(7):527-531.Дедов И.И., Анциферов М.Б., Галстян Г.Р., Токмакова А.Ю. (1998) Синдром диабетической стопы. М.: Универсум Паблишинг, - с.143Дедов И.И., Анциферов М.Б., Галстян Г.Р., Токмакова А.Ю. (1998) Синдром диабетической стопы. М.: Универсум Паблишинг, - с.143Shoppet M., Al-Fakhri N., Franke F., Katz N., Barth P., Maisch B., Preissner K., Hofbauer L. (2004) Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappa B ligand in Monckebergs sclerosis and atherosclerosis. The Journal of Clinical Endocrinology&Metabolism, Vol.89, № 8, 4104-4112.Shoppet M., Al-Fakhri N., Franke F., Katz N., Barth P., Maisch B., Preissner K., Hofbauer L. (2004) Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappa B ligand in Monckebergs sclerosis and atherosclerosis. The Journal of Clinical Endocrinology&Metabolism, Vol.89, № 8, 4104-4112.Abedin M., Tintut Y., Demer L. (2004) Vascular calcification: mechanisms and clinical ramifications. Aterosclerosis, thrombosis, and vascular biology; 24; 1164-1170.Abedin M., Tintut Y., Demer L. (2004) Vascular calcification: mechanisms and clinical ramifications. Aterosclerosis, thrombosis, and vascular biology; 24; 1164-1170.Hofbauer L., Shoppet M. (2001) Osteoprotegerin: a link between osteoporosis and arterial calcification? The Lancet. Vol.358.Hofbauer L., Shoppet M. (2001) Osteoprotegerin: a link between osteoporosis and arterial calcification? The Lancet. Vol.358.Simmonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Dave E., Bucay N., Renshaw-Gregg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. V.89: 309-319.Simmonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Dave E., Bucay N., Renshaw-Gregg L., Hughes T.M., Hill D., Pattison W., Campbell P., Boyle W.J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. V.89: 309-319.Tsuda E., Goto M., Mochizuki S. et al. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibites the osteoclastogenesis. Biochem. Biophys. Res. Comm. V.234 P. 137-142Tsuda E., Goto M., Mochizuki S. et al. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibites the osteoclastogenesis. Biochem. Biophys. Res. Comm. V.234 P. 137-142Tan K.B., Harrop J., Reddy M. Et al. (1997) Characterization of a novel TNF-like ligand and recently described TNF ligand receptor superfamily genes and their constutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. V.204. P.35-46.Tan K.B., Harrop J., Reddy M. Et al. (1997) Characterization of a novel TNF-like ligand and recently described TNF ligand receptor superfamily genes and their constutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. V.204. P.35-46.Шварц Г.Я. (2003) Молекулярно-биологические основы создания новых лекарственных средств для лечения остеопороза: 1. Остеопротегерин, ЛОПГ (RANKL) и RANK: физиологический механизм(ы) регуляции костной резорбции. Обзор литературы. Остеопороз и остеопатии №2. - с.21-22Шварц Г.Я. (2003) Молекулярно-биологические основы создания новых лекарственных средств для лечения остеопороза: 1. Остеопротегерин, ЛОПГ (RANKL) и RANK: физиологический механизм(ы) регуляции костной резорбции. Обзор литературы. Остеопороз и остеопатии №2. - с.21-22Khosla S. (2001) Minireview: the OPG/RANKL/RANK System. Endocrinology 142 (12): 5050-5055Khosla S. (2001) Minireview: the OPG/RANKL/RANK System. Endocrinology 142 (12): 5050-5055Беневоленская Л.И. (2003) Руководство по остеопорозу. М.: БИНОМ. Лаборатория знаний. - с.82Беневоленская Л.И. (2003) Руководство по остеопорозу. М.: БИНОМ. Лаборатория знаний. - с.82Yasuda H., Shima N., Nakagawa N., Mochizucki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 39:1329-1337.Yasuda H., Shima N., Nakagawa N., Mochizucki S.I., Yano K., Fujise N., Sato Y., Goto M., Yamaguchi K., Kuriyama M., Kanno T., Murakami A., Tsuda E., Morinaga T., Higashio K. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 39:1329-1337.Bucay N., Sarosi I., Dunstan C,R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.L., Simonet W.S. (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.Bucay N., Sarosi I., Dunstan C,R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.L., Simonet W.S. (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.Anderson M.A., Maraskovsky E., Billingsley W.L., Dougall W.S., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. (1997) A homologue of the TNF receptor and its ligand enhance Tcell growth and dendritic-cell function. Nature 390:175-179.Anderson M.A., Maraskovsky E., Billingsley W.L., Dougall W.S., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. (1997) A homologue of the TNF receptor and its ligand enhance Tcell growth and dendritic-cell function. Nature 390:175-179.Fuller K., Wong B., Fox S., Choi Y., Chambers T.J. (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp Med 188:997-10001Fuller K., Wong B., Fox S., Choi Y., Chambers T.J. (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp Med 188:997-10001Bekker P.J., Holloway D., Nalanishi A., et.al. (1999) Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J. Bone Mineral Reseach; 14 (Suppl.1):S180.Bekker P.J., Holloway D., Nalanishi A., et.al. (1999) Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J. Bone Mineral Reseach; 14 (Suppl.1):S180.Hofbauer L.C., Shui C., Riggs B.L., et al. (2001) Effects of immunosuppressants on receptor activator of NF-kB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cell. Biochem Biophys Res Commun ; 280:334-39.Hofbauer L.C., Shui C., Riggs B.L., et al. (2001) Effects of immunosuppressants on receptor activator of NF-kB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cell. Biochem Biophys Res Commun ; 280:334-39.Malyankar U.M., Scatena M., Suchland K.L., Yun T.J., Clarc E.A., Giachechelli C.M. (2000) Osteopronegerin is an -induced, NF- Bdependent survival factor for endothelial cells. J. Biol.Chem; 275: 20959-62.Malyankar U.M., Scatena M., Suchland K.L., Yun T.J., Clarc E.A., Giachechelli C.M. (2000) Osteopronegerin is an -induced, NF- Bdependent survival factor for endothelial cells. J. Biol.Chem; 275: 20959-62.Min H., Morony S., Sarosi I., et. al. (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp Med; 192: 463-74.Min H., Morony S., Sarosi I., et. al. (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J. Exp Med; 192: 463-74.Browner W.S., Lui L.Y., Cummings S.R. (2001) Associations of serum osteoprotegerin levels wits diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab; 86: 631-37.Browner W.S., Lui L.Y., Cummings S.R. (2001) Associations of serum osteoprotegerin levels wits diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab; 86: 631-37.Schoppet M., Sattler ANM, Schaefer J.R., Herzum M., Maisch B., Hofbauer L.C. (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin Endocrinol. Metabol., 88: 1024- 1028.Schoppet M., Sattler ANM, Schaefer J.R., Herzum M., Maisch B., Hofbauer L.C. (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin Endocrinol. Metabol., 88: 1024- 1028.Yano K., Tsuda E., Washida N. et al. (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res.; 14:518-27.Yano K., Tsuda E., Washida N. et al. (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res.; 14:518-27.Glass C., Witztum J. (2001) Atherosclerosis: The road ahead. Cell; 104:503-516.Glass C., Witztum J. (2001) Atherosclerosis: The road ahead. Cell; 104:503-516.Parchami F., Morrow A., Balucan J., Leitinger N., Watson A., Tintut Y., Berliner J., Demer L. (1997) Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcifications in osteoporotic patients. Aterosclerosis, thrombosis, and vascular biology; 17; 680-687.Parchami F., Morrow A., Balucan J., Leitinger N., Watson A., Tintut Y., Berliner J., Demer L. (1997) Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcifications in osteoporotic patients. Aterosclerosis, thrombosis, and vascular biology; 17; 680-687.Kon T., Cho T.J., Aizawa T. et al. (2001) Expression of osteoprotegerin, receptor activator of NF-kappa B ligand (osteoprotegerin-ligand) and related proinflammatory cytokines during fracture healing. J. Bone Miner. Res ; 16:1004-1014.Kon T., Cho T.J., Aizawa T. et al. (2001) Expression of osteoprotegerin, receptor activator of NF-kappa B ligand (osteoprotegerin-ligand) and related proinflammatory cytokines during fracture healing. J. Bone Miner. Res ; 16:1004-1014.

The authors declare that there are no conflicts of interest present.